Evidence mapPaperPMID 42016608Full record

ArticleMicrobial cell (Graz, Austria)2026

From the gut to the lungs: The role of gut microbiota in chronic obstructive pulmonary disease and related research progress.

Simin Yang, Shuting Zeng, Yongan Deng, Xiaodong Duan, Chengkai Chen, Luyun Sun, Yongkang Qiao, Zunpeng Shu

Abstract read
In one paragraph

Article in Microbial cell (Graz, Austria), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simin YangSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Shuting ZengSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Yongan DengSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Xiaodong DuanSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Chengkai ChenSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Luyun SunKey Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Department of Biology, Faculty of Arts and Sciences, Beijing Normal University, Zhuhai, 519087, China.
Yongkang QiaoKey Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Department of Biology, Faculty of Arts and Sciences, Beijing Normal University, Zhuhai, 519087, China.
Zunpeng ShuSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease with high morbidity and mortality. Existing treatment methods are difficult to effectively curb disease progression, highlighting the urgency to explore new pathogenesis mechanisms and therapeutic targets. With the development of microbiomics, the proposal of the "gut-lung axis" concept has provided a brand-new perspective for understanding the pathological mechanisms of COPD, revealing that the gut and lungs maintain a close connection through pathways such as immune regulation and metabolic interaction. This article systematically elaborates on the association between gut microbiota and COPD: First, it deeply analyzes the pathological interaction between the gut and lungs from the perspective of the gut-lung axis. On this basis, it examines the characteristic changes in gut microbiota and their metabolites in COPD patients, explores the key influencing factors driving such microbiota dysbiosis, and further systematically explains the core mechanisms by which gut microbiota contribute to the occurrence and progression of COPD. Finally, it focuses on strategies for the prevention and treatment of COPD based on gut microbiota regulation, and prospects their clinical application potential. The purpose of this article is to provide new ideas and directions for the basic research and clinical practice of COPD by comprehensively sorting out the association between gut microbiota and COPD, thereby helping to improve the current status of COPD prevention and treatment.

Indexed as

COPDgut-lung axisgut microbiotagut microbiota metabolitesimmune regulation

Identifiers

PMID42016608
PMCPMC13093826

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.